Aadi Bioscience, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$39.6M
Doctors Paid
583
Transactions
2,682
2024 Total
$21.2M
Payment Breakdown by Category
Research$38.8M (97.9%)
Consulting$342,321 (0.9%)
Food & Beverage$51,210 (0.1%)
Travel$29,303 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $38.8M | 1,512 | 97.9% |
| Honoraria | $366,675 | 141 | 0.9% |
| Consulting Fee | $342,321 | 82 | 0.9% |
| Food and Beverage | $51,210 | 827 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $42,305 | 19 | 0.1% |
| Travel and Lodging | $29,303 | 66 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $14,000 | 4 | 0.0% |
| Education | $5,024 | 31 | 0.0% |
Payments by Type
Research
$38.8M
1,508 transactions
General
$850,838
1,170 transactions
Ownership
$0
4 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/_TSC2 Genes (PRECISION 1) | $14.9M | 0 | 51 |
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1TSC2 Genes PRECISION 1 | $7.1M | 0 | 31 |
| Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer | $6.3M | 0 | 327 |
| A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes | $3.7M | 2 | 467 |
| A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes. | $2.7M | 1 | 271 |
| Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors NETs of the Gastrointestinal Tract Lung or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | $2.5M | 0 | 4 |
| Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract Lung or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | $494,611 | 0 | 315 |
| Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment | $475,934 | 0 | 23 |
| A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions | $294,203 | 0 | 2 |
| Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas | $218,068 | 0 | 8 |
| A Phase 2 Study of ABI-009 in Patients With Advanced Malignant PEComa | $58,869 | 0 | 5 |
| Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | $38,440 | 0 | 4 |
Payments by Medical Specialty
Top Paid Doctors — Page 6
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Sarah Bell, Md, MD | Obstetrics & Gynecology | Ann Arbor, MI | $633.28 | $0 |
| Mrs. Kristi Lara, Pa-C, PA-C | Physician Assistant | Los Angeles, CA | $616.56 | $0 |
| Solange Sierra, Aprn, APRN | Nurse Practitioner | Miami, FL | $586.97 | $0 |
| Dr. Shivaani Kummar | Hematology & Oncology | Portland, OR | $550.00 | $0 |
| Dr. Tyler Gluckman, M.d, M.D | Cardiovascular Disease | Portland, OR | $525.00 | $0 |
| Dr. Manish Sharma, M.d, M.D | Medical Oncology | Grand Rapids, MI | $525.00 | $0 |
| Christopher Ryan, Md, MD | Medical Oncology | Portland, OR | $500.00 | $0 |
| Dr. Hope Rugo, Md, MD | Internal Medicine | San Francisco, CA | $500.00 | $0 |
| Taylor Orellana, M.d, M.D | Student in an Organized Health Care Education/Training Program | Pittsburgh, PA | $407.70 | $0 |
| Erin Hartnett, Md, MD | Gynecologic Oncology | Hartford, CT | $407.70 | $0 |
| Alison Garrett, Md, MD | Obstetrics & Gynecology | Pittsburgh, PA | $407.70 | $0 |
| Larissa Meyer, Md, MD | Gynecologic Oncology | Houston, TX | $391.74 | $0 |
| Emily Jonczak, M.d, M.D | Hematology & Oncology | Miami, FL | $381.30 | $0 |
| Meagan Viel, Np, NP | Family | Grand Rapids, MI | $377.77 | $0 |
| Ms. Alissette Naveda, Arnp, ARNP | Registered Nurse | Miami, FL | $341.37 | $0 |
| Monica Luna, Aprn, APRN | Adult Health | Miami, FL | $341.37 | $0 |
| Jubilee Brown, Md, MD | Obstetrics & Gynecology | Charlotte, NC | $327.92 | $0 |
| Dr. James Hu, M.d, M.D | Medical Oncology | Los Angeles, CA | $295.01 | $0 |
| Debra Kossman, Crnp, CRNP | Adult Health | Philadelphia, PA | $289.76 | $0 |
| Dr. Victoria Rizk, M.d, M.D | Hematology & Oncology | Basking Ridge, NJ | $289.59 | $0 |
| Dr. Vina Nguyen, M. D, M. D | Hospitalist | Fountain Valley, CA | $285.67 | $0 |
| Michael Cho, Md, MD | Internal Medicine | Los Angeles, CA | $285.67 | $0 |
| Dr. Anthony Nguyen, M.d, M.D | Internal Medicine | Sacramento, CA | $272.69 | $0 |
| Dr. Sara Tolaney, Md, MD | Internal Medicine | Boston, MA | $250.00 | $0 |
| Christina Roland, Md, MD | Surgery | Houston, TX | $241.08 | $0 |
About Aadi Bioscience, Inc.
Aadi Bioscience, Inc. has made $39.6M in payments to 583 healthcare providers, recorded across 2,682 transactions in the CMS Open Payments database. In 2024, the company paid $21.2M. The top product by payment volume is FYARRO ($23.1M).
Payments were distributed across 46 medical specialties. The top specialty by payment amount is Medical Oncology ($341,757 to 68 doctors).
Payment categories include: Food & Beverage ($51,210), Consulting ($342,321), Research ($38.8M), Travel & Lodging ($29,303).
Aadi Bioscience, Inc. is associated with 3 products in the CMS Open Payments database.